2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - 295-296
Technology and Procedures, Omics Technologies, Bioinformatics, Treatment Considerations, Biological Therapies, Transplantation, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Metabolism, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Young Adult
PAPER

608 Mitochondrial proteostatic stress contributes to dysregulated granulopoiesis

Michael Joseph Vido, MD, PhD, Gia Bautista2, Julia Warren, MD,PhD3
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Severe congenital neutropenia (SCN) is a leukemia germline predisposition syndrome characterized by bone marrow granulocyte arrest, susceptibility to infection, and increased risk of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). While SCN-associated variants impair granulocyte maturation, their effects on hematopoietic stem and progenitor cells (HSPCs) remain poorly understood. Consequently, the cell-intrinsic stresses that drive adaptive somatic evolution and premalignant clonal hematopoiesis remain poorly defined. As a result, management of SCN patients remains largely supportive with no current therapies available that reduce stress and promote neutrophil differentiation or survival.

To address this knowledge gap, we sought to establish a model of Caseinolytic Peptidase B (CLPB)-mediated SCN. CLPB is a mitochondrial intermembrane chaperone that promotes protein disaggregation and refolding and is on a growing list of mitochondrial proteins whose dysfunction causes SCN. CLPB loss-of-function causes increased granulocyte precursor apoptosis, reduced colony formation, and impaired oxidative phosphorylation. Interestingly, loss of CLPB also causes increased mitochondrial protein translation.

We generated a germline Clpb knockout (KO) mouse strain and characterized the effects on mouse survival and granulopoiesis. In heterozygous crosses, Clpb KO mice were born at sub-Mendelian ratios, exhibited growth failure, and did not survive beyond postnatal day 21. We also observed fetal attrition between E15.5 and birth, with E14.5-E15.5 embryos appearing grossly normal. This early mortality was not due to gross hematopoietic failure, as peripheral blood counts were normal. To test the impact of Clpb loss on granulopoiesis, we evaluated the composition of mature white blood cell lineages at D19-D21 and observed decreased circulating mature neutrophils. Bone marrow analysis demonstrated accumulation of granulocyte-monocyte progenitors (GMPs) and immature neutrophils, consistent with impaired terminal differentiation. Clpb KO bone marrow also harbored fewer phenotypic HSPCs.

To further study impaired granulopoiesis, we generated conditionally immortalized ER-HoxB8 GMP-like cells from Clpb WT or KO littermates. We measured neutrophil output during differentiation of Clpb WT and KO ER-HoxB8 cells and observed persistence of c-kit+ cells and reduced mature neutrophils from Clpb KO cells, recapitulating the differentiation arrest observed in vivo. Given the association between CLPB loss and increased protein translation, we tested whether inhibiting mitochondrial translation with the tetracycline antibiotic doxycycline could reverse the neutrophil differentiation arrest phenotype in Clpb KO granulocytes. Doxycycline treatment increased cell numbers and promoted neutrophil maturation in both Clpb WT and KO ER-HoxB8 cells. Finally, preliminary in vivo studies demonstrated prolonged survival of Clpb KO mice treated with doxycycline.

We have established models of CLPB-mediated SCN that recapitulate key features of human disease, including reduced circulating mature neutrophil counts. The accompanying reduction in phenotypic HSPCs suggests that mitochondrial proteostatic stress may influence earlier hematopoietic compartments, a hypothesis currently being tested in functional transplantation assays. Doxycycline, a known mitochondrial translation inhibitor, partially rescued the differentiation phenotype. Together, these studies establish CLPB deficiency as a model of mitochondrial proteostatic stress that disrupts granulopoiesis and identify mitochondrial translation inhibition as a strategy that partially rescues neutrophil differentiation. These findings identify mitochondrial proteostasis as a fundamental regulator of granulopoiesis and nominate this pathway as a potential therapeutic target in SCN.
Michael Joseph Vido, MD, PhD: No relevant conflicts of interest to declare.